Omeros Corporation To Introduce Its Proprietary T-CAT(TM) Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Stock Information for TSR Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TSR Inc.

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Omeros Corporation Reports First Quarter 2025 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
 Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.